NeurAxis, Inc.
NeurAxis, Inc.
Your view on NRXS
Overview
What the company does, where it operates, and who runs it.
About NeurAxis, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Brian Carrico
- Headquarters
- 11550 North Meridian Street, Carmel, IN, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Brian Carrico
- Headquarters
- 11550 North Meridian Street, Carmel, IN, US
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics.
The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for NeurAxis, Inc., and the rating behind it. NRXS last traded at $5.74; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for NeurAxis, Inc.. Starting points for NeurAxis, Inc.: EPS -$0.65, beta 1.45 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for NeurAxis, Inc.. NeurAxis, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for NeurAxis, Inc.. Trailing twelve-month EPS for NeurAxis, Inc. stands at -$0.65. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for NeurAxis, Inc.. NeurAxis, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
NeurAxis, Inc. valued side by side against its closest peers. NeurAxis, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold NeurAxis, Inc., and how their positions are changing. At a $71.6M market value, institutional positions materially move NeurAxis, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by NeurAxis, Inc. executives and directors. Shares of NeurAxis, Inc. have traded between $1.33 and $6.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming NeurAxis, Inc.. NeurAxis, Inc. is a $71.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming NeurAxis, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for NeurAxis, Inc.. Coverage tracks NeurAxis, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.